News Source: Androscoggin News
| 6 months ago
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided...
News Source: Androscoggin News
| 6 months ago
Amylin Pharmaceuticals, Inc...These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association ( ADA ) in New Orleans . A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S.
News Source: Androscoggin News
| 6 months ago
exenatide) injection was not increased compared to patients initiating other antidiabetic therapies...In keeping with the companies' focus on patient safety, Amylin and Lilly continue to pursue a drug safety program that includes thorough...
News Source: The Courier-Journal
| 6 months ago
Major pharmaceutical companies are fighting harder over the millions of patients with diabetes, a lucrative market because the pool of customers is growing with the obesity epidemic -- and they will need daily drugs for life. As the American...
News Source: The Noblesville Ledger
| 6 months ago
Eli Lilly and Co.'s experimental long-acting version of Byetta lowered blood sugar more than Takeda Pharmaceutical's Actos or Merck's Januvia, and allowed patients to lose more weight, a study showed. Sixty-six percent of diabetics taking Byetta had...
News Source: Androscoggin News
| 6 months ago
Patients with type 2 diabetes over the age of 65 years may achieve better hemoglobin A 1c (HbA 1c ) lowering with insulin glargine treatment added to oral hypoglycemic agents than with the combination of NPH insulin and oral agents, according to...